GENEVA: Moderna said on Thursday it has secured a European Commission contract to supply its respiratory syncytial virus vaccine to six countries in the region. The agreement gives the participating countries — Austria, Denmark, Ireland, Luxembourg, Norway and Portugal — access to up to 24 million doses of the vaccine over as many as four years, the company said. The vaccine, mRESVIA, will be supplied in a ready-to-use, single-dose pre-filled syringe, making administration easier for health care professionals, Moderna said.
Moderna wins EU contract for RSV vaccine supply
The vaccine, mRESVIA, will be supplied in a ready-to-use, single-dose pre-filled syringe
RSV is a common respiratory virus that causes seasonal infections
July 09, 2026 16:34
GENEVA: Moderna said on Thursday it has secured a European Commission contract to supply its respiratory syncytial virus vaccine to six countries in the region.
Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.
mFLUSIVA becomes Moderna's fifth approved product globally and fourth FDA-approved productCompany expects supply to be available…
Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's…
Up to 2000 children aged under-5 are hospitalised with RSV each year.
Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems have…
French babies who received nirsevimab had lower rates of invasive pneumococcal disease
